Han, W and Fan, S and Bai, X and Ding, C, Strontium ranelate, a promising disease modifying osteoarthritis drug, Expert Opinion on Investigational Drugs, 26, (3) pp. 375-380. ISSN 1354-3784 (2017) [Refereed Article]
© 2017 Informa UK
Areas covered: A literature search was performed on PubMed and European Medicines Agency (EMA) website for all publications and documents related to SrR and OA. References of related studies were searched by hand. Treatment with SrR, especially at the dosage of 2 g/day, was associated with reduced radiographic knee OA progression, and with meaningful clinical improvement. It was also significantly associated with decreased MRI-assessed cartilage volume loss (CVL) and bone marrow lesions (BMLs).
Expert opinion: SrR could be a promising DMOAD particularly for OA patients with bone phenotypes. The clinical efficacy and side effects of SrR for OA treatment need to be further investigated in future clinical trials before clinical application.
|Item Type:||Refereed Article|
|Keywords:||Strontium ranelate, disease-modifying osteoarthritis drug (DMOAD), osteoarthritis (OA)|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Clinical sciences|
|Research Field:||Rheumatology and arthritis|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Ding, C (Professor Chang-Hai Ding)|
|Web of Science® Times Cited:||18|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page